Global and United States Myeloproliferative Disorders Drugs Market Report & Forecast 2024-2031

Report ID: 1835326 | Published Date: Jan 2025 | No. of Page: 88 | Base Year: 2024 | Rating: 3.8 | Webstory: Check our Web story
1 Study Coverage
    1.1 Myeloproliferative Disorders Drugs Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Myeloproliferative Disorders Drugs Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Myeloproliferative Disorders Drugs Market Size for the Year 2017-2028
        1.2.2 Global Myeloproliferative Disorders Drugs Market Size for the Year 2017-2028
    1.3 Myeloproliferative Disorders Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Myeloproliferative Disorders Drugs in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Myeloproliferative Disorders Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Myeloproliferative Disorders Drugs Market Dynamics
        1.4.1 Myeloproliferative Disorders Drugs Industry Trends
        1.4.2 Myeloproliferative Disorders Drugs Market Drivers
        1.4.3 Myeloproliferative Disorders Drugs Market Challenges
        1.4.4 Myeloproliferative Disorders Drugs Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Myeloproliferative Disorders Drugs by Type
    2.1 Myeloproliferative Disorders Drugs Market Segment by Type
        2.1.1 Ph+ CML
        2.1.2 Ph- MPN
    2.2 Global Myeloproliferative Disorders Drugs Market Size by Type (2017, 2022 & 2028)
    2.3 Global Myeloproliferative Disorders Drugs Market Size by Type (2017-2028)
    2.4 United States Myeloproliferative Disorders Drugs Market Size by Type (2017, 2022 & 2028)
    2.5 United States Myeloproliferative Disorders Drugs Market Size by Type (2017-2028)
3 Myeloproliferative Disorders Drugs by Application
    3.1 Myeloproliferative Disorders Drugs Market Segment by Application
        3.1.1 Hospitals
        3.1.2 Pharmacy
    3.2 Global Myeloproliferative Disorders Drugs Market Size by Application (2017, 2022 & 2028)
    3.3 Global Myeloproliferative Disorders Drugs Market Size by Application (2017-2028)
    3.4 United States Myeloproliferative Disorders Drugs Market Size by Application (2017, 2022 & 2028)
    3.5 United States Myeloproliferative Disorders Drugs Market Size by Application (2017-2028)
4 Global Myeloproliferative Disorders Drugs Competitor Landscape by Company
    4.1 Global Myeloproliferative Disorders Drugs Market Size by Company
        4.1.1 Top Global Myeloproliferative Disorders Drugs Companies Ranked by Revenue (2021)
        4.1.2 Global Myeloproliferative Disorders Drugs Revenue by Player (2017-2022)
    4.2 Global Myeloproliferative Disorders Drugs Concentration Ratio (CR)
        4.2.1 Myeloproliferative Disorders Drugs Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Myeloproliferative Disorders Drugs in 2021
        4.2.3 Global Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Myeloproliferative Disorders Drugs Headquarters, Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Myeloproliferative Disorders Drugs Headquarters and Area Served
        4.3.2 Global Myeloproliferative Disorders Drugs Companies Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Myeloproliferative Disorders Drugs Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Myeloproliferative Disorders Drugs Market Size by Company
        4.5.1 Top Myeloproliferative Disorders Drugs Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Myeloproliferative Disorders Drugs Revenue by Players (2020, 2021 & 2022)
5 Global Myeloproliferative Disorders Drugs Market Size by Region
    5.1 Global Myeloproliferative Disorders Drugs Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Myeloproliferative Disorders Drugs Market Size by Region (2017-2028)
        5.2.1 Global Myeloproliferative Disorders Drugs Market Size by Region: 2017-2022
        5.2.2 Global Myeloproliferative Disorders Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Myeloproliferative Disorders Drugs Market Size YoY Growth 2017-2028
        6.1.2 North America Myeloproliferative Disorders Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Myeloproliferative Disorders Drugs Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Myeloproliferative Disorders Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Myeloproliferative Disorders Drugs Market Size YoY Growth 2017-2028
        6.3.2 Europe Myeloproliferative Disorders Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Myeloproliferative Disorders Drugs Market Size YoY Growth 2017-2028
        6.4.2 Latin America Myeloproliferative Disorders Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Myeloproliferative Disorders Drugs Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Myeloproliferative Disorders Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE
7 Company Profiles
    7.1 Celgene
        7.1.1 Celgene Company Details
        7.1.2 Celgene Business Overview
        7.1.3 Celgene Myeloproliferative Disorders Drugs Introduction
        7.1.4 Celgene Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.1.5 Celgene Recent Development
    7.2 Bristol-Myers Squibb
        7.2.1 Bristol-Myers Squibb Company Details
        7.2.2 Bristol-Myers Squibb Business Overview
        7.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Introduction
        7.2.4 Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.2.5 Bristol-Myers Squibb Recent Development
    7.3 Gamida Cell
        7.3.1 Gamida Cell Company Details
        7.3.2 Gamida Cell Business Overview
        7.3.3 Gamida Cell Myeloproliferative Disorders Drugs Introduction
        7.3.4 Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.3.5 Gamida Cell Recent Development
    7.4 Incyte
        7.4.1 Incyte Company Details
        7.4.2 Incyte Business Overview
        7.4.3 Incyte Myeloproliferative Disorders Drugs Introduction
        7.4.4 Incyte Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.4.5 Incyte Recent Development
    7.5 Geron
        7.5.1 Geron Company Details
        7.5.2 Geron Business Overview
        7.5.3 Geron Myeloproliferative Disorders Drugs Introduction
        7.5.4 Geron Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.5.5 Geron Recent Development
    7.6 Promedior
        7.6.1 Promedior Company Details
        7.6.2 Promedior Business Overview
        7.6.3 Promedior Myeloproliferative Disorders Drugs Introduction
        7.6.4 Promedior Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.6.5 Promedior Recent Development
    7.7 Johnson and Johnson
        7.7.1 Johnson and Johnson Company Details
        7.7.2 Johnson and Johnson Business Overview
        7.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Introduction
        7.7.4 Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2017-2022)
        7.7.5 Johnson and Johnson Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer
List of Tables
    Table 1. Myeloproliferative Disorders Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Myeloproliferative Disorders Drugs Market Trends
    Table 3. Myeloproliferative Disorders Drugs Market Drivers
    Table 4. Myeloproliferative Disorders Drugs Market Challenges
    Table 5. Myeloproliferative Disorders Drugs Market Restraints
    Table 6. Global Myeloproliferative Disorders Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Myeloproliferative Disorders Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Myeloproliferative Disorders Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Myeloproliferative Disorders Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Myeloproliferative Disorders Drugs Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Myeloproliferative Disorders Drugs Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Myeloproliferative Disorders Drugs Revenue Share by Player, 2017-2022
    Table 13. Global Myeloproliferative Disorders Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Myeloproliferative Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myeloproliferative Disorders Drugs as of 2021)
    Table 15. Top Players of Myeloproliferative Disorders Drugs in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Myeloproliferative Disorders Drugs Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Myeloproliferative Disorders Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Myeloproliferative Disorders Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Myeloproliferative Disorders Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Myeloproliferative Disorders Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Myeloproliferative Disorders Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Myeloproliferative Disorders Drugs Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Myeloproliferative Disorders Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Myeloproliferative Disorders Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Myeloproliferative Disorders Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Myeloproliferative Disorders Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Myeloproliferative Disorders Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Celgene Company Details
    Table 31. Celgene Business Overview
    Table 32. Celgene Myeloproliferative Disorders Drugs Product
    Table 33. Celgene Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 34. Celgene Recent Development
    Table 35. Bristol-Myers Squibb Company Details
    Table 36. Bristol-Myers Squibb Business Overview
    Table 37. Bristol-Myers Squibb Myeloproliferative Disorders Drugs Product
    Table 38. Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 39. Bristol-Myers Squibb Recent Development
    Table 40. Gamida Cell Company Details
    Table 41. Gamida Cell Business Overview
    Table 42. Gamida Cell Myeloproliferative Disorders Drugs Product
    Table 43. Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 44. Gamida Cell Recent Development
    Table 45. Incyte Company Details
    Table 46. Incyte Business Overview
    Table 47. Incyte Myeloproliferative Disorders Drugs Product
    Table 48. Incyte Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 49. Incyte Recent Development
    Table 50. Geron Company Details
    Table 51. Geron Business Overview
    Table 52. Geron Myeloproliferative Disorders Drugs Product
    Table 53. Geron Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 54. Geron Recent Development
    Table 55. Promedior Company Details
    Table 56. Promedior Business Overview
    Table 57. Promedior Myeloproliferative Disorders Drugs Product
    Table 58. Promedior Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 59. Promedior Recent Development
    Table 60. Johnson and Johnson Company Details
    Table 61. Johnson and Johnson Business Overview
    Table 62. Johnson and Johnson Myeloproliferative Disorders Drugs Product
    Table 63. Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2017-2022) & (US$ Million)
    Table 64. Johnson and Johnson Recent Development
    Table 65. Research Programs/Design for This Report
    Table 66. Key Data Information from Secondary Sources
    Table 67. Key Data Information from Primary Sources
List of Figures
    Figure 1. Myeloproliferative Disorders Drugs Product Picture
    Figure 2. Global Myeloproliferative Disorders Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Myeloproliferative Disorders Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. United States Myeloproliferative Disorders Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Myeloproliferative Disorders Drugs Market Size 2017-2028 (US$ Million)
    Figure 6. United States Myeloproliferative Disorders Drugs Market Share in Global 2017-2028
    Figure 7. Myeloproliferative Disorders Drugs Report Years Considered
    Figure 8. Product Picture of Ph+ CML
    Figure 9. Product Picture of Ph- MPN
    Figure 10. Global Myeloproliferative Disorders Drugs Market Share by Type in 2022 & 2028
    Figure 11. Global Myeloproliferative Disorders Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 12. Global Myeloproliferative Disorders Drugs Market Share by Type (2017-2028)
    Figure 13. United States Myeloproliferative Disorders Drugs Market Share by Type in 2022 & 2028
    Figure 14. United States Myeloproliferative Disorders Drugs Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. United States Myeloproliferative Disorders Drugs Market Share by Type (2017-2028)
    Figure 16. Product Picture of Hospitals
    Figure 17. Product Picture of Pharmacy
    Figure 18. Global Myeloproliferative Disorders Drugs Market Share by Application in 2022 & 2028
    Figure 19. Global Myeloproliferative Disorders Drugs Market Size by Application (2017-2028) & (US$ Million)
    Figure 20. Global Myeloproliferative Disorders Drugs Market Share by Application (2017-2028)
    Figure 21. United States Myeloproliferative Disorders Drugs Market Share by Application in 2022 & 2028
    Figure 22. United States Myeloproliferative Disorders Drugs Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. United States Myeloproliferative Disorders Drugs Market Share by Application (2017-2028)
    Figure 24. North America Myeloproliferative Disorders Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 25. U.S. Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 26. Canada Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 27. Europe Myeloproliferative Disorders Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. Germany Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. France Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. U.K. Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Italy Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Russia Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Myeloproliferative Disorders Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 34. China Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Japan Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. South Korea Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. India Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Australia Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Taiwan Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Indonesia Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Thailand Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Malaysia Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Philippines Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Latin America Myeloproliferative Disorders Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 45. Mexico Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Brazil Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Argentina Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Myeloproliferative Disorders Drugs Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Turkey Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Saudi Arabia Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. UAE Myeloproliferative Disorders Drugs Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Celgene Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 54. Gamida Cell Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 55. Incyte Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 56. Geron Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 57. Promedior Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 58. Johnson and Johnson Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2017-2022)
    Figure 59. Bottom-up and Top-down Approaches for This Report
    Figure 60. Data Triangulation
    Figure 61. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
Frequently Asked Questions
Myeloproliferative Disorders Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Myeloproliferative Disorders Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Myeloproliferative Disorders Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cholera Vaccines

Cholera Vaccines market is segmented by region (country), players, by Type and by Application. Pl ... Read More